R1 RCM Stock Forecast, Price & News

-0.89 (-4.24%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
925,761 shs
Average Volume
1.17 million shs
Market Capitalization
$5.59 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive RCM News and Ratings via Email

Sign-up to receive the latest news and ratings for R1 RCM and its competitors with MarketBeat's FREE daily newsletter.

R1 RCM logo

About R1 RCM

R1 RCM, Inc. engages in the provision of revenue cycle management to healthcare providers. It offers end-to-end, modular revenue cycle, and physician advisory services. The company was founded by Mary Ann Tolan and J. Michael Cline in July 2003 and is headquartered in Chicago, IL.


See More Headlines

Industry, Sector and Symbol

Management services
Health Care Services
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$1.27 billion
Cash Flow
$1.47 per share
Book Value
$0.73 per share


Net Income
$117.10 million
Pretax Margin




Free Float
Market Cap
$5.59 billion
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.26 out of 5 stars

Finance Sector

428th out of 1,349 stocks

Management Services Industry

3rd out of 9 stocks

Analyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

R1 RCM (NASDAQ:RCM) Frequently Asked Questions

Is R1 RCM a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" R1 RCM stock.
View analyst ratings for R1 RCM
or view top-rated stocks.

How has R1 RCM's stock price been impacted by Coronavirus?

R1 RCM's stock was trading at $10.16 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RCM stock has increased by 98.0% and is now trading at $20.12.
View which stocks have been most impacted by COVID-19

When is R1 RCM's next earnings date?

R1 RCM is scheduled to release its next quarterly earnings announcement on Thursday, February 17th 2022.
View our earnings forecast for R1 RCM

How were R1 RCM's earnings last quarter?

R1 RCM Inc. (NASDAQ:RCM) issued its earnings results on Tuesday, November, 2nd. The healthcare provider reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.08 by $0.03. The healthcare provider had revenue of $379.70 million for the quarter, compared to the consensus estimate of $372.87 million. R1 RCM had a net margin of 9.96% and a trailing twelve-month return on equity of 40.83%.
View R1 RCM's earnings history

What guidance has R1 RCM issued on next quarter's earnings?

R1 RCM updated its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.46 billion-$1.48 billion, compared to the consensus revenue estimate of $1.47 billion.

What price target have analysts set for RCM?

7 analysts have issued 12 month price targets for R1 RCM's stock. Their forecasts range from $27.00 to $35.00. On average, they anticipate R1 RCM's share price to reach $29.86 in the next year. This suggests a possible upside of 48.4% from the stock's current price.
View analysts' price targets for R1 RCM
or view top-rated stocks among Wall Street analysts.

Who are R1 RCM's key executives?

R1 RCM's management team includes the following people:
  • Joseph Gerard Flanagan, President, Chief Executive Officer & Director
  • John Sparby, COO, Executive VP-Operations & Delivery (LinkedIn Profile)
  • Rachel Wilson, Chief Financial Officer, Treasurer & Executive VP
  • Julia K. Davis, Chief Information Officer & Executive VP
  • Jay Sreedharan, Chief Technology & Digital Officer

What is Joseph Flanagan's approval rating as R1 RCM's CEO?

253 employees have rated R1 RCM CEO Joseph Flanagan on Joseph Flanagan has an approval rating of 70% among R1 RCM's employees.

What other stocks do shareholders of R1 RCM own?

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), (JD), Baozun (BZUN), Inseego (INSG), BioXcel Therapeutics (BTAI), Marvell Technology (MRVL), Akoustis Technologies (AKTS), Alibaba Group (BABA), Bilibili (BILI) and Model N (MODN).

What is R1 RCM's stock symbol?

R1 RCM trades on the NASDAQ under the ticker symbol "RCM."

Who are R1 RCM's major shareholders?

R1 RCM's stock is owned by a number of institutional and retail investors. Top institutional investors include Spire Wealth Management (0.01%), Crossmark Global Holdings Inc. (0.01%) and State of Alaska Department of Revenue (0.01%). Company insiders that own R1 RCM stock include Achi Series Lllp Tcp-Asc, Albert Rene Zimmerli, Alex Mandl, Gary Steven Long, John M Sparby, Joseph Gerard Flanagan, Michael C Feiner and Richard B Jr Evans.
View institutional ownership trends for R1 RCM

Which institutional investors are selling R1 RCM stock?

RCM stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., State of Alaska Department of Revenue, and Spire Wealth Management. Company insiders that have sold R1 RCM company stock in the last year include Achi Series Lllp Tcp-Asc, Alex Mandl, Gary Steven Long, John M Sparby, Joseph Gerard Flanagan, and Richard B Jr Evans.
View insider buying and selling activity for R1 RCM
or view top insider-selling stocks.

How do I buy shares of R1 RCM?

Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is R1 RCM's stock price today?

One share of RCM stock can currently be purchased for approximately $20.12.

How much money does R1 RCM make?

R1 RCM has a market capitalization of $5.59 billion and generates $1.27 billion in revenue each year. The healthcare provider earns $117.10 million in net income (profit) each year or ($2.01) on an earnings per share basis.

How many employees does R1 RCM have?

R1 RCM employs 20,200 workers across the globe.

Does R1 RCM have any subsidiaries?

The following companies are subsidiares of R1 RCM: Accretive Health Mauritius Inc., Advanced Data Processing Inc., Cerner RevWorks, Intermedix, Intermedix ARM LLC, Intermedix Analytics LLC, Intermedix Corporation, Intermedix Holdings Inc., Intermedix Lietuva UAB, Intermedix Midco Inc., Intermedix Office Based LLC, Intermedix Physician Services LLC, Intermedix Staffing Inc., Med Media Inc., Medical Consultants Inc., Optima (NZ) Limited, Optima (US) LTD, Practice Support Resources LLC, Project Links Parent Inc., R1 RCM Global Private Limited, R1 RCM India Private Limited, Rover16 Inc., SCI Solutions, The DeZonia Group Inc., The Optima Corporation (International) LTD, The Optima Corporation Limited, and The Optima Corporation PTY LTD.

When was R1 RCM founded?

R1 RCM was founded in 2003.

What is R1 RCM's official website?

The official website for R1 RCM is

Where are R1 RCM's headquarters?

How can I contact R1 RCM?

R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The healthcare provider can be reached via phone at (312) 324-7820, via email at [email protected], or via fax at 302-655-5049.

This page was last updated on 1/17/2022 by Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.